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The evolution of a rheumatic attack involves three distinct clinical 
phases  (1,  2).  The  first  is  an  acute  respiratory infection,  usually 
of not more than 3 days duration.  The second is an afebrile, symp- 
tom-free period which may vary somewhat but  commonly lasts  14 
days.  The third is the period of acute rheumatism, composed of one 
or more cycles of activity.  Cycles consist of about  10  to  14  days 
of  disease  activity  separated  from  each  other by  7  to  10  days  of 
remission.  Of these three phases,  the second appears  to be  crucial 
in the genesis of rheumatic activity.  In an intensive study of this 
symptom-free period we have detected in the past only one abnormal- 
ity, a  diminution of serum complement (3). 
Investigators in Jena  (4), Wurzburg  (5), Turin  (6), Jerusalem (7) 
and  New York  (3),  are  agreed  that  during  acute  rheumatic fever 
serum  complement may  fluctuate  from  the  normal  to  low  levels, 
becoming  steady  at  a  normal  level  with  recovery.  With  the  ex- 
ception  of acute nephritis  (8)  and  serum sickness)  a  wide variety 
of  other  diseases  show  little  or  no  variation  in  the  complement 
level  (9). 
Whether the decrease in titratable complement observed during the 
course of rheumatic fever is  a  result of the rheumatic process or a 
factor in the pathogenesis of the disease cannot be decided a  priori. 
However, the decrease which occurs in phase II, before the onset of 
acute  rheumatism,  is  definitely not  a  result of rheumatic activity, 
* The work reported in this communication was carried out under The W. K. 
Kellogg Foundation Fund. 
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lending further support to the possibility that the phenomenon may 
be a  factor in the pathogenesis of the rheumatic attack. 
Decreases in serum complement are known to occur when there are 
present in the circulation both an antigen and its antibody, with the 
former in excess.  This suggested that during phase II, when comple- 
ment  is  diminished  an  excess  of  some  antigen  might  be  present. 
Should such an antigen occur, its antibody should then be present in 
excess shortly after the return of complement to normal, that is in the 
course of phase III.  We have therefore looked for evidence of both 
antigen  and  antibody in  the  form of mutual  precipitation  between 
sera of phase III (presumptive antibody) and sera from phases II and 
I  (presumptive  antigen). 
EXPER~NTAL  PROCEDURE 
Selection of Pa~ients.--Serial blood samples  were taken at least once a week 
from rheumatic subjects recovering  from hemolytic streptococcus pharyngitis, 
and from non-rheumatic controls.  Single blood samples were taken from control 
patients with other febrile disease and from individuals  in good health. 
Preparation of Sera.--Sera were preserved with  merthiolate and  stored  at 
5°C. for periods up to 6 months.  Before being tested, they were cleared by high 
speed centrifugafion and, when necessary, by filtration through a Pasteur-Cham- 
berland candle L2. 
The  Precipitin  Test.--Chemically  clean  precipitin  tubes  and  pipettes  were 
used exclusively.  Undiluted sera were  tested against  one another for mutual 
precipitation.  0.1  ce.  of antibody serum was  layered over 0.1  cc.  of antigen 
serum.  Three readings were recorded as follows, the third being the one reported 
throughout this paper:  (a)  Ring formation after 10 minutes at room temperature. 
(b)  Precipitation after mixing  and incubation for 2 hours in a  37  ° water bath. 
(c)  Precipitation after refrigeration overnight at 5°C.  The intensity of precipita- 
tion is expressed as in previous communications  (10). 
+ + +  large flakes. 
+ + ±  large and small flakes. 
+ +  small flakes or granules supernatant clear. 
+ ±  numerous flakes or granules appearing in cloudy whirl. 
+  cloudy whirl. 
0 clear. 
-  not tested. 
Preliminary  Observations 
It  was  soon  observed  that  sera  taken  at  the  height  of  an  acute 
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before the onset of symptoms.  Pairs of sera which reacted with each 
other were then tested separately against other sera from the same 
patient,  as tabulated in the following sample protocol. 
Phase  Date 
I  May 10 
II  "  18 
"  22 
III  "  24 
"  28 
June  1 
Phase I 
(May 10) 
m 
o 
Phase II 
(May 18) 
+ 
++ 
+ 
[  (May 22) 
0 
I  m 
++ 
Phase llI (cycle I) 
(May 24) 
0 
+ 
m 
m 
(May 28) 
0 
++ 
++ 
0 
(June  I) 
0 
+ 
0 
These findings showed that  precipitation  occurred only between 
phase II  and phase  III  sera.  In at least six other patients known 
positive phase II sera were tested against each other and known posi- 
tive phase III sera were also tested in pairs.  No reactions occurred 
between any of these combinations.  This limitation of the reaction 
to the combination of phases II  and III furnished a  plan on which 
extensive investigations were based.  Sera from phase II  (and also, 
when  available,  from  phase  I)  were  tested  as  potential  antigens 
against sera from phase III. 
Precipitin  Reactions  in  Acute  Rheumatism 
The first data to be discussed are from seventeen rheumatic sub- 
jects  who  developed  rheumatic fever following  hemolytic strepto- 
coccus pharyngitis during the winter and spring of  1938.  Four of 
these attacks were mild, five of moderate intensity, five severe, and 
three were of extreme intensity.  Illustrative patients  are listed in 
Table I, in order of increasing severity. 
This group includes those patients who had rheumatic attacks in 
1938 from whom sera were obtained before the onset of symptoms. 
They were  quiescent  rheumatic subjects  who  had  been  under our 
observation for a number of years.  They were selected for study at 
this  time  because  each  had  contracted  a  bacteriologically proven 
streptococcal pharyngitis.  All but one showed precipitins during the 
acute attack to an antigen present in their own serum just before the TABLE  I 
Precipitin Reactions  between Potential  Antigens and  Potential  Antibodies  in Sera 
from Patients  with Acute Rheumatism 
Patient 
Bou 
Ale 
Sco 
Sat 
Hall 
Phase III 
sera 
(time after 
infection) 
days 
30 
32 
36 
39 
4O 
43 
47 
51 
65 
47 
49 
51 
54 
56 
59 
66 
73 
80 
87 
16 
17 
20 
23 
24 
31 
38 
45 
52 
59 
18 
20 
22 
24 
28 
30 
34 
36 
38 
42 
16 
19 
24 
27 
31 
35 
Phase I 
Potential antigens taken during 
Phase II 
*Early  Middle  Late 
* Early, middle, late  = 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  0  0 
0  0  +  + 
0  0  +  + 
0  0  0  + 
0  0  0  0 
0  0  0  0 
0  --  0  + 
0  --  0  + 
0  --  0  + 
0  --  0  + 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  +± 
0  --  0  ++ 
0  --  0  ++ 
0  --  0  0 
0  --  0  0 
0  --  0  0 
0  --  0  0 
m 
m 
0 
0 
m 
1st, 2nd, 3rd week 
146 
m 
m 
m 
m 
m 
0 
4- 
4-4- 
4-4- 
4- 
0 
0 
0 
0 
0 
++ 
4-++ 
4- 
4-4- 
+4- 
+4-4- 
Character of attack 
Mild 
Moderate 
Severe 
Fulminating 
Recovery 
Fu|m!~atlng 
Died (autopsied) 
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onset of the attack.  Sera taken at 2 to 3 day intervals showed that 
the concentration of antigen was maximal just before the symptoms 
appeared and that it disappeared within 3 days thereafter.  In five 
cases enough sera were obtained before the onset of rheumatism to 
establish the fact that the antigens with which the above precipitins 
reacted were not present during pharyngitis but appeared in phase 
II.  In  one of these cases  sera  taken  during the month preceding 
pharyngitis were  also free  of antigen.  The  precipitin appeared in 
each case  during the peak of the rheumatic cycle and disappeared 
with subsidence.  The most intense reactions were observed in sera 
from  the  severest  attacks.  One  individual with  rapidly fatal  ful- 
minating rheumatism gave  the  strongest  precipitin  reaction  of  all 
cases studied. 
Precipitin Reactions Following Uncomplicated Streptococcus Infections 
without Rheumatism 
All the patients presented in Table I  had had hemolytic strepto- 
coccus pharyngitis.  The possibility that the precipitin reaction was 
associated with pharyngitis rather than rheumatism was therefore in- 
vestigated.  In order to determine the serological behavior of patients 
who recovered from hemolytic streptococcus without developing rheu- 
matism, two control groups were studied.  These consisted of twenty 
non-rheumatic subjects  and  twenty-seven rheumatic subjects  with 
uncomplicated respiratory infections.  Sera obtained during the first 
21  days after infection were tested  as potential antigens, and sera 
obtained thereafter as potential antibodies. 
The results of these tests were negative except in three patients 
who  developed precipitins  4  to  5  weeks  after  infection.  In  one 
of these the antibody serum reacted only with serum from the period 
of  acute  infection  (phase I).  In  the  other  two the antibody sera 
reacted with serum taken 2 weeks after infection; that is, their serolog- 
ical behavior was similar to  that seen in  the rheumatic group.  It 
is of interest that,  of these two,  one had  to  be  readmitted to  the 
hospital because of abdominal pain accompanied by a high sedimenta- 
tion rate.  This occurred at the time that the precipitins were present. 
The second control group consisted of twenty-seven rheumatic sub- 
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pharyngitis but escaped all clinical and laboratory signs of rheumatic 
activity.  The  sera were assigned  to  serve as antigens  or antibodies 
TABLE  II 
Precipitin Reactions between Potential Antigens and Potential Antibodies in Sera 
from Rheumatic Subjects with Pharyngitis  Who Escaped Recrudescences 
Patient 
Deu 
Eas 
Fei 
Kir 
Sav 
Potential 
antibodies (time 
after infection)  During acute 
infection 
Potential antigens taken 
Following acute infection 
16  0 
19  + 
21  + 
23  0 
26  0 
28  + 
30  0 
36 
43  4- 
20  4- 
24  4- 
31  4-4- 
52  4-+ 
33  0 
45  4- 
59  0 
17  0 
24  + 
38  0 
52  0 
28  4-+ 
35  4- 
42  o 
56  4- 
1st wk.  2nd wk. 
o  o 
+  + 
+  + 
+  + 
+  + 
4-±  4-+ 
-t--4-  4-4- 
4-4-  4- 
4-4-  4- 
4-  0 
+  0 
4-4-  +4- 
4-4-  4- 
0  0 
4-  4-+ 
0  0 
4-  0 
4-  4- 
0  0 
0  0 
4-±  4-± 
4-  4- 
0  4- 
4-  0 
just as in the preceding group.  The positive results of the precipitin 
tests are presented in Table II. 
The results of these tests were negative in twenty-two cases.  These 
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precipitins to some substance present during the acute infection and 
for the next 2 weeks.  None of the precipitating sera were positive 
to  phase  II  (the  time  corresponding to  the  symptom-free period) 
unless they were also positive to phase I  (acute infection).  These 
precipitins remained strong in three patients for at least 2  months 
after infection, in the absence of all symptoms.  This type of reaction 
appeared on further investigation to be  distinct from  that  of acute 
rheumatism (see page 158). 
Precipitin Reactions in Patients with Polycyclic Courses 
The data presented so far were confined to the first cycle of acute 
rheumatism, and in most cases it was clear that the precipitin pres- 
ent  at  the  height of  the  cycle  decreased  as  disease  activity  sub- 
sided.  The next point investigated was whether precipitating sera 
would recur with repeated cycles of rheumatic activity.  It was found 
that sera taken at the height of cycle II contained good precipitins 
for phase II antigen.  The data are presented in Table III. 
It will be noted in Table III that precipitins for phase II antigen 
recurred  during  the  second  cycle  of  rheumatic  activity.  It  will 
also be observed that precipitins disappeared from the sera during 
the  periods  of  remission between  cycles  of  activity.  When  these 
remission sera which did not contain antibody were retested as anti- 
gens against  known positive  cycle  II  antibodies,  precipitation was 
once more observed.  The occurrence of antigen during a  remission 
between cycles is illustrated in Table IV. 
Antibodies appearing in cycles  I  and  II both precipitated  phase 
II antigen.  Furthermore, antibodies appearing in  cycle  II  precipi- 
tated antigens developed during the remission between cycles.  To 
demonstrate the identity of the phase II and remission antigens, it 
was necessary only to show that remission antigens would form a pre- 
cipitate with cycle I  antibody sera,  which preceded them in  time. 
The reactions of remission antigens with antibodies which preceded 
and followed are given in Table IV.  The data in Tables III and IV 
leave no doubt that the antigens of phase II and remission sera are of 
similar reactivity. 
It  has  often been observed that  a  rheumatic subject can escape 
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to develop acute rheumatism some weeks later,  at the time that a 
second cycle would ordinarily be  anticipated.  One patient in  our 
1938  series behaved in this  manner.  Sera were collected from the 
onset of pharyngitis, and the patient was kept under close observa- 
TABLE  III 
Precipitin Reactions between Sera Taken during  the Second  Cycle of Acute 
Rheumatism and Sera Taken during Phase II 
Antibodies 
Patient  Antigens (phase n)  Clinical comment 
Cycle  Date 
(Apr. 3)  (Apr, 8) 
San  I  Apr.  19  0  +  Acute rheumatic attack 
"  21  +  + 
"  28  0  0 
II  May  10  0  0 
17  0  0 
"  25  +4"  +-4- 
June  7  0  0 
Low 
(Apr. 7)  (Apr. 14) 
I  Apr.  23  +  + 
"  28  0  0 
May 14  +  + 
"  19  +  + 
"  21  0  0 
"  28  0  0 
June  4  0  0 
II  "  18  0  0 
"  25  0  + 
"  27  0  + 
Ter  II 
(Jan. 27)  (Feb.  3) 
Mar.  7  0  0 
"  I0  0  + 
"  12  +  +± 
Remission Apr. 30 to May 7 
Another cycle 
Vague symptoms 
High blood sedimentation rate 
Acute rheumatic attack 
Second cycle of acute rheumatislx 
tion in the hospital.  So far as could be determined, she escaped all 
evidences  of  rheumatic  activity  for  6  weeks  after  the  infection, 
and then developed a mild but definite attack  of acute rheumatism. 
During the first month after infection, it appeared that the patient 
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TABLE  IV 
Precipitin Reactions between Sera  Taken during tke Remission between Cycles and 
Sera Taken during the First and Second Cycles 
Patient 
Pag 
Lem 
Cycle 
II 
Antibodies 
Date 
May  3 
"  5 
"  10 
Antigens (from remission between 
(A~. 29) 
+± 
+ 
+ 
cycles I and II) 
I  Mar.  8 
"  12 
"  22 
II  Apr.  9 
"  11 
"  13 
"  16 
"  18 
"  21 
"  25 
"  27 
"  29 
(Mar.  28)  (Apr.  5) 
+±  ++ 
+±  ++ 
+±  ++ 
+  + 
+  + 
+  + 
+  + 
+  ++ 
0  + 
+  + 
0  0 
0  0 
(Apr. 7) 
0 
+ 
+± 
+ 
+ 
+ 
+ 
++ 
+ 
+ 
O 
0 
TABLE  V 
The Late Development of Positive  Precipitin Reactions  in a Patient with a Delayed 
Attack ~ ' Acute Rheumatism 
Antibodies 
Stage of disease 
Period usually correspond- 
ing to cycle I 
Date 
Feb.  4 
"  7 
"  I1 
Mar.  2 
"  7 
"  14 
"  21 
Period of  acute  rheuma- 
~am 
Antigens 
Period usually corresponding to 
Phase I 
(Jan.  2o) 
0 
0 
0 
Phase II 
(Jan. 26)  (Feb. 2) 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
0  0 
Remission after cycle I 
of phase Ill 
(Feb. 19) 
0 
0 
+ 
+ 
(Feb. 24)  (Feb. 261 
0  0 
0  0 
0  0 
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or antibody.  However, she did develop an attack at a  time which 
would ordinarily correspond with a  second cycle.  Coincident with 
this, precipitins appeared to serum taken one week before the onset of 
symptoms.  The  findings  on  this  patient  are  given  in  Table  V. 
Experiments Dealing with Cross-Reactions between Patients 
All the reactions reported so far occurred between sera of different 
dates  from  the  same  patient  (hereafter termed  homologous  sera). 
The  next point  investigated was  whether these  reactions  could be 
duplicated between antigens  and  antibodies from different patients 
TABLE  VI a 
Precipitin Reactions between Homologous and Heterologous Sera 
Patient 
Phi 
Sco 
Sci 
Sut 
Antigens 
Stage of disease 
Phase II 
Phase II 
Phase H 
Phase II 
Antibodies 
Type 
Homologous 
Heterologous 
Homologous 
Heterologous 
Homologous 
Heterologous 
Homologous 
Heterologous 
Stage of disease 
Phase III 
Phase III 
Phase III 
Phase III 
Phase III 
Phase IH 
Phase III 
Phase III 
Precipitin 
reaction 
+4- 
+4- 
++ 
+ 
+ 
+4- 
+4- 
+4- 
(heterologous  sera).  Observations  on  this  point  are  presented  in 
Table VIa. 
Table  VIa  shows that heterologous sera gave precipitation  reac- 
tions of approximately the same intensity as homologous sera when 
tested against the same known antigens or antibodies.  The reactions 
are  therefore not  patient-specific.  This  point  was  further  studied 
by  checking the  development of precipitinogen  in  phase  II.  The 
earliest positive antibody serum from each of two patients was tested 
against  potential  antigen  sera  from  one  of  them.  In  both  cases 
positive reactions occurred with a single antigen serum, taken 14 days 
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to both homologous and heterologous antibody.  The data are sum- 
marized in Table VI b. 
A  similar  experiment  was  run  in  which  the  development  of pre- 
cipitin  in  phase  III  was  determined  by  tests  with  three  different 
antigens.  As can be seen in Table VIc when a number  of antibody 
sera from one patient  were tested against  positive homologous and 
heterologous  antigens,  differences in  the  intensity  of  reaction  were 
apparent.  These  differences  seemed  to  reflect  differences  in  the 
strength  of the antigens. 
TABLE VI b 
Development of Precipitinogen in Phase II Sera as Determined by Reactions with 
Homologous and Heterologous Antibody 
Antibodies 
Phase III 
Potential antigens, patient Sci 
Phase I  Phase II 
Sci (10th day of attack) ..................  0  0  +  0 
Hah (5th day of attack) ..................  0  0  +-4-  0 
TABLE  VI  C 
The Development of Precipitin  in Phase III Sera as Determined by Reactions with 
Homologous and tteterologous Antigens 
Antigens  Potential antibodies (Sci) 
Phase n  Phase UI 
(Mar. 10)  (Mar. 15)  (Mar. 22) 
Scl Feb. 26 (weak) .......................  0  +  4- 
Sut May 26 (strong) ......................  +4-  -4-4-  + 
All  the  antibody  sera  referred  to  in  Table  VI  were  known  to 
contain precipitin from preliminary positive reactions with their own 
sera.  The next subject of inquiry was whether sera from all patients 
with  acute  rheumatism  would  precipitate  known  positive  antigen 
sera.  To test this point, antigen sera from the two patients in Table 
VIb were set up against the sera of nine patients with  acute rheuma- 
tism.  Two  sera  taken  some  days  apart  were  tested  from  each 
patient,  to  ensure at  least  one  at  an  appropriate  time in the  rheu- 
matic cycle.  The results are detailed in Table VII. 
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acute  rheumatism  admitted  to  the  hospital  wards  some  time  after 
the  onset  of  symptoms.  No  homologous antigens  were  available. 
The  sera  of  eight  of  these  patients  contained precipitins  for heter- 
TABLE  VII 
Precipitin Reactions  of Sera from  Patients  with  Acute  Rheumatism  with  Two 
Heterologous Sera Known to Contain Antigen 
Patient (potential antibodies) 
Ace 
Bar 
Bra 
DeB 
Kau 
Ros 
Smi 
Ste 
Wol 
Jan.  8 
"  24 
Mar. 14 
~t  24 
Oct. 21 
"  27 
Dec.  27 
Jan.  3 
Dec.  20 
"  29 
Mar.  2 
"  9 
Feb.  10 
"  23 
Mar.  7 
"  8 
Dec.  23 
"  29 
Hah 
+ 
+± 
0 
+ 
0 
+ 
0 
+4- 
+ 
+ 
+ 
0 
+ 
++ 
+ 
0 
0 
0 
Antigens 
o 
+ 
o 
+± 
0 
+4- 
o 
+ 
+4- 
+ 
o 
+ 
+ 
+ 
ologous antigen.  The  data  in  Tables  V  to VII,  inclusive,  indicate 
that this precipitation reaction is not patient-specific, but will occur 
between  sera  of  any  rheumatic  patients  provided  that  such  sera 
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Experiments  Dealing with the Specificity of the Reactions for 
Rheumatic  Fever 
The foregoing data have indicated that during post-streptococcal 
convalescence, the precipitin reaction occurred only in  acute  rheu- 
matism with  the  exceptions discussed.  We  have  just shown that 
the  reaction  is  not  patient-specific.  Whether  it  is  disease-specific 
was next investigated. 
First it was ascertained that normal sera were consistently negative 
to one another and to the sera of acute rheumatism at all stages of 
disease  activity.  ~  Then it  was found that neither fever nor rapid 
blood sedimentation paralleled the occurrence of the precipitin re- 
action.  Sera  taken during high fevers  (associated  with  tonsillitis, 
lymphosarcoma,  leukemia,  tuberculosis,  undulant  fever)  and  sera 
from rapidly sedimenting bloods (associated with post-streptococcM 
acute nephritis, pneumonia and tuberculosis) were consistently nega- 
tive to phase II antigen.  Reactions did not occur when either antigen 
or antibody was replaced by serum from other acute febrile diseases. 
Another possibility investigated was  that  this reaction might be 
related  to  the  non-specific precipitation  of  pneumococcus C  sub- 
stance reported to occur in acute rheumatism by Tillett and Francis 
(11).  The  sera  from  seven  patients  with  acute  rheumatism were 
found to contain strong precipifins for a 1 : 50,000 dilution of pneumo- 
coccus C.  It was  also found that,  with one exception, the sera of 
twenty patients who were recovering from streptococcal throat in- 
fections but who did not have acute rheumatism, failed to precipitate 
pneumococcus  C  substance.  These  observations  supported  the 
possibility that the precipitin reaction might be related to the precipi- 
tation of pneumococcus C substance.  If such were the case, it should 
be possible to  establish  (1)  that phase II  antigen reacts with anti- 
pneumococcus sera and (2) that the precipitin of phase III antibody 
for phase II antigen should be removed by absorption with pneumo- 
The sera of one patient who developed acute rheumatism in the 6th month of 
pregnancy showed  completely divergent behavior.  They gave strong positive 
reactions with all homologous sera, with heterologous rheumatic sera, with normal 
sera, even with rabbit sera.  As the same thing was found to be true for normal 
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coccus  C  substance.  Experiments  on  these  points  were  therefore 
set up:-- 
1.  Known positive phase  II  antigens were tested with sera from 
four patients with lobar pneumonia and with horse and rabbit anti- 
pneumococcus sera.  These pneumonia sera precipitated C substance 
but did not precipitate the rheumatic phase II antigens. 
2.  Positive phase III sera from four cases of acute rheumatismwere 
treated with pneumococcus C.  Following absorption, they failed to 
precipitate  C  substance  but  still  precipitated  rheumatic phase  II 
antigens, both homologous and heterologous.  An illustrative protocol 
is seen in Table VIII. 
TABLE  VIII 
The E~rect of Absorption  with Pneuraococcus C on the Precipitation  of Phase II 
Antigens 
Patient Cal 
Antibody Apr. 12 
Unabsorbed .............................. 
After absorption with C .................... 
After control absorption with saline* ......... 
Antigens 
Pn  C 
++ 
0 
0 
Homologous  Heterologous 
Cal Mar. 41  Low Apr. 14 
+a=  + 
+a=  + 
+  + 
* Weakening of the pneumococcus C reaction in sera subjected to absorption 
with saline was observed repeatedly.  Simple  dilution of serum with saline, how- 
ever, did not produce this effect. 
These two findings indicate that the precipitin reactionof rheumatic 
fever is  not  related  to the  non-specific pneumococcus  C  reaction 
common to a number of febrile diseases. 
The  Relation  of  the  Rheumatic  Precipitin  Reaction  to  Streptococcal 
Derivatives 
The next experiment was done to determine whether the precipitin 
to phase II antigen was an antistreptococcal immune body.  This was 
investigated in  two  different ways:  (A)  by  testing  known  positive 
phase III antibody sera for antibodies to various well known fractions 
of hemolytic streptococcus; and (B) by testing known positive phase 
II sera for streptococcus antigens. 
Five known positive phase III antibodies were each tested against 
the following streptococcus fractions:  C (group-specific carbohydrate), 
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throat culture taken during phase I.  Three of the sera were negative 
to C, and two others to P, indicating that in certain patients anti-C 
and anti-P are not involved in the observed precipitin reaction.  The 
data are presented in Table IX a. 
All of the antibody sera contained anti-M at some timeduring phase 
III; however, the reactions of phase III antibody with M  substance 
TABLE  IX d~ 
Precipitin Reactions of Phase III Sera with Streptococcal Fractions and Homologous 
Phase II Sera 
Ale 
Cal 
Kea 
Lena 
Sut 
Antibodies 
May 21 
Apr.  12 
"  18 
"  9 
June  6 
Antigens 
Streptococcal  Homologous 
phaseII  M  C  P 
++ 
+4- 
0 
++ 
o 
++ 
0 
0 
++ 
± 
++ 
o 
o 
++ 
+ 
+ 
+ 
+ 
++ 
TABLE  IX b 
The Effect of A bsorbing Phase III Antibody with M  Substance on the Precipitation  of 
Phase II Antigen 
Antigens 
Patient Sut (type 15 or 17) 
Antibody 
Unabsorbed  .............................. 
Absorbed with M-15 ...................... 
Absorbed with M-17 ...................... 
Control absorption with saline ............. 
M-15 
+ 
o 
o 
+ 
M-17 
+ 
0 
0 
0 
Homologous 
phase II 
antigen May 26 
++ 
+ 
+ 
+ 
did not parallel their reactions with phase II antigen (five cases ex- 
amined).  This  suggested  but  did  not  prove  the  independence of 
rheumatic precipitin and anti-M.  Phase III antibody sera from four 
cases  were  therefore absorbed,  each with  its  own  type-specific M 
substance (previously determined from throat culture isolated during 
phase  I)  to  determine whether the  precipitin  to  phase  II  antigen 
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sera  no  longer  precipitated  M  substance  but  did  still  precipitate 
phase II antigen.  A  typical experiment is presented in Table IX b. 
Secondly, known positive phase II antigens were tested with four 
antistreptococcal therapeutic sera known to contain antitoxin, anti-P 
and anti-C.  These reactions were all negative.  Similar tests  were 
performed on antigens from the same patients whose throat infections 
had been typed, using type-specific anti-M rabbit sera.  The results 
were again negative as seen in Table X. 
These  findings indicate  that  the  phase  II  antigen  is  not  one of 
the four streptococcal products investigated.  Phase III sera contain 
several antibodies to hemolytic streptococcus; but the precipitin to 
TABLE  X 
Predpitation of Rheumatic Antigenz by Type-Specific Anti-M Rabbit Serum and 
Homologous Phase IH Serum 
Type No. 
15 
29 
30 
30 
30 
$ut 
Lem 
Cal 
Kea 
Sci 
Antigens 
June  6 
Mar.  3 
"  31 
Apr. 18 
"  19 
Antibodies 
Type-sl~cific 
ant1-M 
rabbit serum 
Homologous 
phase HI serum 
+ 
+ 
+ 
+ 
+ 
phase II antigen seems to be distinct from the bacterial  antibodies 
investigated. 
The Nature of Positive Reactions in Rheumatic Subjects  Who Escaped 
Rheumatic Attacks 
It was seen in Table II that a few individuals who escaped rheumatic 
attacks nevertheless developed antibodies  in  phase  III  (page  148). 
These  sera  precipitated  all those  which  preceded  them,  not  only 
phase  II  but  also  phase  I.  In  other  words,  the  antigen  involved 
was already present during phase I.  The question raised  by  these 
patients was whether the precipitin of these phase III sera was the 
same as the precipitin in phase  III  sera of rheumatic subjects who 
developed  attacks.  To  throw  light  on  this  problem,  the  sera  in ALVIN  •.  COBURN  AND  RUTH  H.  PAULI  159 
question were tested with known positive antigens of patients who 
had developed attacks.  The results are shown in Table XI. 
From Table XI it is seen that the precipitin observed in these two 
patients was distinct from the precipitin which followed the develop- 
ment of acute rheumatism. 
The  Nature  of  Negative  Reactions 
The next point to be investigated was the reason for the negative 
reactions observed between pairs  of homologous sera  taken during 
recovery from  throat  infections.  In  these  cases,  where  both sera 
were of unknown character, failure to form a  precipitate may have 
been  due  to  the  absence  of  antigen, or  antibody,  or  both;  or  to 
TABLE  XI 
The Absence of Precipitin Reactions between Known Positive Phase II Antigens and 
Antibodies from Patients Who Escaped Attacks 
Antibodies positive 
to phase I 
Deu  Apr. 11 
Eas  "  22 
Antigens 
From phase I not fol-  [  From phase II followed by attacks 
lowed by attack~  .  (heterologons) 
Deu  [  Eas  a  [  b  c  d 
+±  I  ++  [  o  ]  o  I~l  o 
+±  I  +  I  o  ]  o  i  o  i  o 
their  presence  in  unsuitable  proportions.  Accordingly potential 
antigens and potential antibodies which had been negative to  their 
homologous sera were retested against known positive antibodies and 
antigens, respectively, to determine which of the essentials of a positive 
reaction was missing. 
A.  Negative Reactions in Rheumatic Subjects Who Escaped A ttacks.-- 
Antibodies.--The  first experiment of this type was set up to retest 
the  precipitating  power  of  two  potential  antibody  sera  from  four 
rheumatic subjects who recovered from pharyngitis without develop- 
ing  acute  rheumatism.  Eight  of  these  sera  were  tested  with  four 
known positive phase II antigen sera.  The results shown were nega- 
tive, indicating that antibodies to phase II antigen were absent from 
all of eight sera reexamined. 
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homologous sera  collected  about  4  weeks  after  infection, were  re- 
tested  with  known  positive  rheumatic  antibodies.  The  data  are 
presented in Table XII.  Half of these  rheumatic subjects, who es- 
caped  attacks  and  who  did  not  produce  precipitins,  nevertheless 
developed some antigen which could be precipitated by  known posi- 
tive heterologous antibodies. 
TABLE  XII 
Precipitin Reactions between Apparently Negative Phase II Antigens (from Rheu- 
matic Subjects Who Escaped Attacks) and Known Positive Phase III Antibodies 
Potential antigens 
Ale  Mar.  5 
All  "  31 
Car  "  31 
Pau  Apr.  7 
Kov  Mar. 25 
Ham  "  10 
Lal  Apr.  18 
Nor  May  14 
Kir  Feb.  26 
McA  Apr.  25 
Antibodies 
Known positive phase IH  Homolo- 
gous  For  A'e  Kea  Low  Sut 
(Apr.  20) I (May  26)  (Apr.  20-------~  ~  ---- 
0 
0 
+  + 
(June 14) 
o 
+ 
o 
o 
o 
+ 
B.  Negative  Reactions  in  Non-Rheumatic  Subjects.-- 
Antigens.--It  has  been  previously  shown  that  some  rheumatic 
subjects who escaped rheumatism following hemolytic streptococcus 
infections developed antigen without forming antibodies to it.  The 
next experiment was  done  to  determine whether in  non-rheumatic 
subjects who showed no precipitin reaction an antigen was likewise 
present.  Sera from ten patients taken about 2 weeks postinfection 
were  retested with four known positive precipifins from phase III 
of acute rheumatism. 
Of  the thirty-two tests,  only one gave a  positive reaction.  The 
number of cases is too small for final conclusions; but the observations 
suggest  that  non-rheumatic subjects  do  not  develop  an  antigenic 
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DISCUSSION 
Although it is not the purpose of the present study to identify the 
precipitinogen with which the foregoing experiments deal, it is clear 
that  the  reaction  is  distinct  from  the  precipitation  of  pneumo- 
coccus  C  substance  and  of  certain  of  the  streptococcus  antigens. 
It  is,  of  course,  possible  that  the  phenomenon  observed  does  not 
represent an antigen-antibody reaction. 
Whatever  its  nature  may prove  to  be,  as  a  working hypothesis 
this precipitinogen may be considered either a primary or secondary 
antigen.  Its absence in sera taken during phase I and its late appear- 
ance in phase II would seem to be against its direct bacterial origin, 
although this cannot be excluded.  Another possibility is a secondary 
antigen  such  as  the  precipitinogen  described  by  Hughes  in  yellow 
fever (12).  It has been shown (13, 3) that in rheumatic subjects who 
develop acute rheumatism, the appearance of circulating antibodies 
to  hemolytic  streptococcus  is  characteristically  late.  During  this 
delay streptococcal products are presumably free to react with human 
tissue  constituents.  Such an interaction  might  result  in  the  pre- 
cipitinogen with which we are dealing. 
SUMMARY 
1.  A precipitin reaction occurs between sera taken just before and 
shortly after the onset of acute rheumatism. 
2.  It recurs with repeated rheumatic cycles. 
3.  Certain properties of the precipitinogen and the precipitin are 
described. 
The  authors  are  indebted  to  Dr.  Kenneth  Goodner for his  sug- 
gestions. 
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